Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 2/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036219 | 0.91 | KDM2B (0.46) | KDM2BL3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL15536106 | 0.86 | KDM2B (0.38) | KDM2BL3MBTL3USP2DRD2DRD4 | |
| SCHEMBL24036217 | 0.83 | KDM2B (0.42) | KDM2BL3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL24036232 | 0.83 | HCAR3 (0.41) | KDM2BL3MBTL3L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL22290560 | 0.78 | GPR119 (0.50) | L3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL30636828 | 0.77 | PARP2 (0.38) | KDM2BL3MBTL3L3MBTL1CHRM3CHRM4 | |
| SCHEMBL24036220 | 0.75 | ALDH1A1 (0.40) | MEN1KMT2ASCN1ASCN2ASCN3A | |
| SCHEMBL29064949 | 0.75 | TSHR (0.33) | KDM2BUSP2ALDH1A1 | |
| SCHEMBL24035853 | 0.75 | TSHR (0.33) | KDM2BUSP2ALDH1A1 | |
| SCHEMBL30695500 | 0.74 | KDM2B (0.40) | KDM2BL3MBTL3L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116710430-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4149459-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | KDM2B 4011/4885L3MBTL3 150/4885L3MBTL1 138/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | KDM2B 4011/4885L3MBTL3 150/4885L3MBTL1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.